The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Overactive Bladder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
- Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
- Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical , Sumitovant Biopharma, Dong-A ST, Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Novartis, Astellas Pharma US, Inc., Pfizer, GlaxoSmithKline, and others, are developing therapies for the Overactive Bladder treatment
- Emerging Overactive Bladder therapies such as – ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, URO-902, BAY 1817080, TAC-302, Mirabegron, Vibegron, Darifenacin, Vesicare, SPM 907, Solabegron, Oxybutynin, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
- In March 2021, Sumitovant Biopharma acquired all the outstanding shares of Urovant Sciences and after acquisition UrovantSciences become the subsidiary of Sumitovant Biopharma. Through this acquisition, Sumitovant Biopharma acquired all thepipeline products of Urovant Sciences.
Overactive Bladder Overview
The term “overactive bladder” (OAB) refers to a collection of urine symptoms. It’s not an illness. The sudden, uncontrollable desire or urge to urinate is the most typical symptom. OAB is defined as a condition with the defining symptoms of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology,” as modified by the International Continence Society in 2010.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
- ARD-380: Aardvark Therapeutics
- URB937: Exxel Pharma
- Botulax: Hugel
- IMB-115: Imbrium Therapeutics
- TAC-302: Taiho Pharmaceutical
- URO-902: Sumitovant Biopharma
- DA-8010: Dong-A ST
- URO-902: Urovant Sciences
- BAY 1817080: Bayer
- TAC-302: Taiho Pharmaceutical
- Mirabegron: Astellas Pharma Inc
- Vibegron: Kyorin Pharmaceutical/Urovant Sciences
- Darifenacin: Novartis
- Vesicare: Astellas Pharma US, Inc.
- SPM 907: Pfizer
- Solabegron: GlaxoSmithKline
- Oxybutynin: Bayer
Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligoncleotide
- Peptides
- Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
- Overactive Bladder Assessment by Product Type
- Overactive Bladder By Stage and Product Type
- Overactive Bladder Assessment by Route of Administration
- Overactive Bladder By Stage and Route of Administration
- Overactive Bladder Assessment by Molecule Type
- Overactive Bladder by Stage and Molecule Type
DelveInsight’s Overactive Bladder Report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are – Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Novartis, Pfizer, GlaxoSmithKline, AbbVie, Medytox, Velicept Therapeutics, Sumitovant Biopharma, Hugel, Imbrium Therapeutics, Lipella Pharmaceuticals, Sumitovant Biopharma, Aetas Pharma, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
- Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
Overactive Bladder Pipeline Market Drivers
- Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
- However, lack of diagnosis and information about Overactive Bladder, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
- Coverage: Global
- Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical , Sumitovant Biopharma, Dong-A ST, Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Novartis, Astellas Pharma US, Inc., Pfizer, GlaxoSmithKline, and others
- Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, URO-902, BAY 1817080, TAC-302, Mirabegron, Vibegron, Darifenacin, Vesicare, SPM 907, Solabegron, Oxybutynin, and others
- Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
- Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Overactive Bladder Report Introduction |
|
2 |
Overactive Bladder Executive Summary |
|
3 |
Overactive Bladder Overview |
|
4 |
Overactive Bladder- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Overactive Bladder Pipeline Therapeutics |
|
6 |
Overactive Bladder Late Stage Products (Phase II/III) |
|
7 |
Overactive Bladder Mid Stage Products (Phase II) |
|
8 |
Overactive Bladder Early Stage Products (Phase I) |
|
9 |
Overactive Bladder Preclinical Stage Products |
|
10 |
Overactive Bladder Therapeutics Assessment |
|
11 |
Overactive Bladder Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Overactive Bladder Key Companies |
|
14 |
Overactive Bladder Key Products |
|
15 |
Overactive Bladder Unmet Needs |
|
16 |
Overactive Bladder Market Drivers and Barriers |
|
17 |
Overactive Bladder Future Perspectives and Conclusion |
|
18 |
Overactive Bladder Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services